Severe Asthma in Primary Care: Identification and Management

American Journal of Medicine

Volumn 131, Issue 5, 2018, Pages 484-491

  Trevor, Jennifer L ^a   Chipps, Bradley E ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Capital Allergy and Respiratory Disease Center   (United States)

Author keywords

Asthma; Biologic therapy; Biomarkers; Endotypes; Phenotypes; Severe; Uncontrolled

Indexed keywords

BENRALIZUMAB; CORTICOSTEROID; FASENRA; IMMUNOGLOBULIN E; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 5; MEPOLIZUMAB; OMALIZUMAB; RESLIZUMAB; ANTIASTHMATIC AGENT; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CYTOKINE; NITRIC OXIDE; POSTN PROTEIN, HUMAN;

ASTHMA; BIOLOGICAL THERAPY; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG TARGETING; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HUMAN; LUNG FUNCTION TEST; MEDICATION COMPLIANCE; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PHENOTYPE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEVERE ASTHMA; SPIROMETRY; BLOOD; EOSINOPHILIA; METABOLISM; PHYSIOLOGY; PRIMARY HEALTH CARE; SEVERITY OF ILLNESS INDEX;

ANTI-ASTHMATIC AGENTS; ASTHMA; BIOMARKERS; CELL ADHESION MOLECULES; CYTOKINES; EOSINOPHILIA; HUMANS; IMMUNOGLOBULIN E; NITRIC OXIDE; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; SEVERITY OF ILLNESS INDEX;

EID: 85045404228     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2017.12.034     Document Type: Review

References (47)

1. Centers for Disease Control and Prevention, 2012 National Health Interview Survey (NHIS) data. Available at: https://www.cdc.gov/asthma/nhis/2012/data.htm. (Accessed 24 May 2017)
2. Centers for Disease Control and Prevention, Asthma Facts—CDC's National Asthma Control Program Grantees. 2013, US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga.
3. Chung, K.F., Wenzel, S.E., Brozek, J.L., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 (2014), 343–373.
4. Chipps, B.E., Zeiger, R.S., Borish, L., et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 130 (2012), 332–342 e310.
5. Carr, T.F., Bleecker, E., Asthma heterogeneity and severity. World Allergy Organ J, 9, 2016, 41.
6. Tai, A., Tran, H., Roberts, M., Clarke, N., Wilson, J., Robertson, C.F., The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax 69 (2014), 805–810.
7. McGeachie, M.J., Yates, K.P., Zhou, X., et al. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med 374 (2016), 1842–1852.
8. Nunes, C., Pereira, A.M., Morais-Almeida, M., Asthma costs and social impact. Asthma Res Pract, 3, 2017, 1.
9. Bahadori, K., Doyle-Waters, M.M., Marra, C., et al. Economic burden of asthma: a systematic review. BMC Pulm Med, 9, 2009, 24.
10. Price, D., Bjermer, L., Bergin, D.A., Martinez, R., Asthma referrals: a key component of asthma management that needs to be addressed. J Asthma Allergy 10 (2017), 209–223.
11. Rance, K.S., Helping patients attain and maintain asthma control: reviewing the role of the nurse practitioner. J Multidiscip Healthc 4 (2011), 299–309.
12. Murphy, K.R., Meltzer, E.O., Blaiss, M.S., Nathan, R.A., Stoloff, S.W., Doherty, D.E., Asthma management and control in the United States: results of the 2009 Asthma Insight and Management survey. Allergy Asthma Proc 33 (2012), 54–64.
13. Schierhorn, C., Avoiding pitfalls in caring for patients with asthma. Available at: https://thedo.osteopathic.org/2014/03/avoiding-pitfalls-in-caring-for-patients-with-asthma, 2014. (Accessed 26 September 2017)
14. O'Byrne, P.M., Pedersen, S., Schatz, M., et al. The poorly explored impact of uncontrolled asthma. Chest 143 (2013), 511–523.
15. Skloot, G.S., Asthma phenotypes and endotypes: a personalized approach to treatment. Curr Opin Pulm Med 22 (2016), 3–9.
16. Global Initiative for Asthma, Global strategy for asthma management and prevention. Available at: http://www.ginasthma.org. (Accessed 24 May 2017)
17. National Heart, Lung and Blood Institute, National asthma education and prevention program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007, 2007, NHLBI Health Information Center, Bethesda, Md.
18. Cordier, T., Slabaugh, S.L., Havens, E., et al. A health plan's investigation of Healthy Days and chronic conditions. Am J Manag Care 23 (2017), e323–e330.
19. Qoltech, Measurement of health-related quality of life & asthma control. Available at: http://www.qoltech.co.uk/index.htm. (Accessed 29 November 2017)
20. Juniper, E.F., Bousquet, J., Abetz, L., Bateman, E.D., GOAL Committee. Identifying “well-controlled” and “not well-controlled” asthma using the Asthma Control Questionnaire. Respir Med 100 (2006), 616–621.
21. Optum, Asthma control test. Available at: https://campaign.optum.com/optum-outcomes/what-we-do/disease-specific-health-surveys/asthma-control-test-act.html. (Accessed 27 November 2017)
22. Nathan, R.A., Sorkness, C.A., Kosinski, M., et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 113 (2004), 59–65.
23. Johnson, J.D., Theurer, W.M., A stepwise approach to the interpretation of pulmonary function tests. Am Fam Physician 89 (2014), 359–366.
24. Dinakar, C., Chipps, B.E., Section on Allergy and Immunology, Section on Pediatric Pulmonology and Sleep Medicine. Clinical tools to assess asthma control in children. Pediatrics, 139, 2017, 10.1542/peds.2016-3438.
25. Blain, E.A., Craig, T.J., The use of spirometry in a primary care setting. Int J Gen Med 2 (2009), 183–186.
26. Sweeney, J., Patterson, C.C., Menzies-Gow, A., et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax 71 (2016), 339–346.
27. Manson, S.C., Brown, R.E., Cerulli, A., Vidaurre, C.F., The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 103 (2009), 975–994.
28. Amelink, M., de Groot, J.C., de Nijs, S.B., et al. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol 132 (2013), 336–341.
29. Canonica, G.W., Senna, G., Mitchell, P.D., O'Byrne, P.M., Passalacqua, G., Varricchi, G., Therapeutic interventions in severe asthma. World Allergy Organ J, 9, 2016, 40.
30. Robinson, D., Humbert, M., Buhl, R., et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy 47 (2017), 161–175.
31. Demarche, S.F., Schleich, F.N., Paulus, V.A., Henket, M.A., Van Hees, T.J., Louis, R.E., Asthma control and sputum eosinophils: a longitudinal study in daily practice. J Allergy Clin Immunol Pract 5 (2017), 1335–1343 e5.
32. Chipps, B.E., Corren, J., Israel, E., et al. Asthma Yardstick: practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma. Ann Allergy Asthma Immunol 118 (2017), 133–142 e133.
33. Varricchi, G., Senna, G., Loffredo, S., Bagnasco, D., Ferrando, M., Canonica, G.W., Reslizumab and eosinophilic asthma: one step closer to precision medicine?. Front Immunol, 8, 2017, 242.
34. Fajt, M.L., Wenzel, S.E., Development of new therapies for severe asthma. Allergy Asthma Immunol Res 9 (2017), 3–14.
35. Genentech, Inc., XOLAIR (Omalizumab Injection), Solution for Subcutaneous Use [package insert]. 2017, Genentech, Inc. A Member of the Roche Group, South San Francisco, Calif.
36. GlaxoSmithKline LLC, NUCALA (Mepolizumab Injection), Solution for Subcutaneous Use [package insert]. 2017, GlaxoSmithKline LLC, Philadelphia, Pa.
37. Teva Respiratory, LLC, CINQAIR (Reslizumab Injection), Solution for Subcutaneous Use [package insert]. 2016, Teva Respiratory, LLC, Frazer, Pa.
38. AstraZeneca AB, FASENRA (Benralizumab) [package insert]. 2017, AstraZeneca AB, Södertälje, Sweden.
39. Laviolette, M., Gossage, D.L., Gauvreau, G., et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132 (2013), 1086–1096 e1085.
40. Kolbeck, R., Kozhich, A., Koike, M., et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125 (2010), 1344–1353 e1342.
41. Nair, P., Wenzel, S., Rabe, K.F., et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 376 (2017), 2448–2458.
42. Bleecker, E.R., FitzGerald, J.M., Chanez, P., et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388 (2016), 2115–2127.
43. FitzGerald, J.M., Bleecker, E.R., Nair, P., et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388 (2016), 2128–2141.
44. AstraZeneca, Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma. press release; November 14, 2017.
45. Wenzel, S., Castro, M., Corren, J., et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388 (2016), 31–44.
46. Wenzel, S., Ford, L., Pearlman, D., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368 (2013), 2455–2466.
47. Wilhelm, C.P., Chipps, B.E., Bronchial thermoplasty: a review of the evidence. Ann Allergy Asthma Immunol 116 (2016), 92–98.